The relationship between COVID-19 and the onset of neurodegenerative disease: clinical case
- 作者: Mirzaeva L.M.1, Lobzina A.S.1, Goldobin V.V.1, Yushko M.V.1, Bubnova P.D.1, Lalova M.Y.1, Zuev A.A.1, Akhmedova K.N.1
-
隶属关系:
- Mechnikov North-Western State Medical University
- 期: 卷 36, 编号 4 (2025)
- 页面: 24-30
- 栏目: Problem
- URL: https://journals.rcsi.science/0236-3054/article/view/290935
- DOI: https://doi.org/10.29296/25877305-2025-04-05
- ID: 290935
如何引用文章
详细
In this article the relationship between COVID-19 and the onset of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease is observed. Possible mechanisms of pathogenesis are discussed: activation of microglia, formation of neurofibrillary tangles and amyloid plaques, which indicates a possible acceleration of pathological processes characteristic of neurodegenerative diseases. A review of the literature suggests that COVID-19 may act as a catalyst for the development or acceleration of neurodegenerative processes. The article presents a clinical observation of a patient admitted to the therapeutic department due to a hypertensive crisis, who developed mixed dementia after COVID-19 infection. The results of clinical and biochemical blood tests are within the reference values. On MRI of the brain – atrophy of the medial temporal lobe, signal changes in the basal ganglia, foci of vascular genesis. On EEG: Disorganized EEG type with dominance of slow activity in the theta rhythm range. Psychodiagnostics revealed cognitive decline to the level of moderate dementia (according to the MMSE scale – 13 scores). The importance of long-term monitoring of patients with post-COVID syndrome and the development of strategies for the prevention and treatment of neurodegenerative diseases in the context of the pandemic is emphasized.
作者简介
L. Mirzaeva
Mechnikov North-Western State Medical University
编辑信件的主要联系方式.
Email: salud@yandex.ru
ORCID iD: 0000-0001-9392-1789
SPIN 代码: 5331-5670
Candidate of Medical Sciences
俄罗斯联邦, Saint PetersburgA. Lobzina
Mechnikov North-Western State Medical University
Email: salud@yandex.ru
ORCID iD: 0000-0001-9048-6822
SPIN 代码: 1811-7065
Candidate of Medical Sciences
俄罗斯联邦, Saint PetersburgV. Goldobin
Mechnikov North-Western State Medical University
Email: salud@yandex.ru
ORCID iD: 0000-0001-9245-8067
SPIN 代码: 4344-5782
MD, Professor
俄罗斯联邦, Saint PetersburgM. Yushko
Mechnikov North-Western State Medical University
Email: salud@yandex.ru
俄罗斯联邦, Saint Petersburg
P. Bubnova
Mechnikov North-Western State Medical University
Email: salud@yandex.ru
俄罗斯联邦, Saint Petersburg
M. Lalova
Mechnikov North-Western State Medical University
Email: salud@yandex.ru
俄罗斯联邦, Saint Petersburg
A. Zuev
Mechnikov North-Western State Medical University
Email: salud@yandex.ru
ORCID iD: 0000-0002-6163-5718
SPIN 代码: 4457-3510
Candidate of Medical Sciences, Associate Professor
俄罗斯联邦, Saint PetersburgK. Akhmedova
Mechnikov North-Western State Medical University
Email: salud@yandex.ru
ORCID iD: 0009-0007-0302-6694
SPIN 代码: 2700-6702
俄罗斯联邦, Saint Petersburg
参考
- Министерство здравоохранения России [Ministry of Health of Russia (in Russ.)]. URL: https://minzdrav.gov.ru/
- Wang Q., Davis P.B., Gurney M.E. et al. COVID-19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 2021; 17 (8): 1297–306. doi: 10.1002/alz.12296
- Информационное телеграфное агентство России (ТАСС) [Information Telegraph Agency of Russia (TASS) (in Russ.)]. URL: https://tass.ru/
- Лобзин В.Ю., Литвиненко И.В., Пушкарев В.А. Когнитивные нарушения у перенесших COVID-19: "туман в голове" или дебют нейродегенерации? Бюллетень Национального общества по изучению болезни Паркинсона и расстройств движений. 2022; 2: 138–40 [Lobzin V.Yu., Litvinenko I.V., Pushkarev V.A. Cognitive impairment in COVID-19 survivors: “brain fog” or the onset of neurodegeneration? Bulletin of the National Parkinson's Disease and Movement Disorder Society. 2022; 2: 138–40 (in Russ.)]. doi: 10.24412/2226-079Х-2022-12452
- Кабыш С.С., Карпенкова А.Д., Прокопенко С.В. Когнитивные нарушения и COVID-19. Сибирское медицинское обозрение. 2022; 2: 40–8 [Kabysh S.S., Karpenkova A.D., Prokopenko S.V. Cognitive impairments and COVID-19. Siberian Medical Review. 2022; 2: 40–8 (in Russ.)]. doi: 10.20333/25000136-2022-2-40-48
- Современная тактика ведения пациентов с постковидным синдромом. Медицинский совет. 2022; 16 (6): 50–8 [A modern approach to the management of patients with post-COVID syndrome. Medical Council. 2022; 6: 50–8 (in Russ.)]. doi: 10.21518/2079-701X-2022-16-6-50-58
- Хасанова Д.Р., Житкова Ю.В., Васкаева Г.Р. Постковидный синдром: обзор знаний о патогенезе, нейропсихиатрических проявлениях и перспективах лечения. Неврология, нейропсихиатрия, психосоматика. 2021; 13 (3): 93–8 [Khasanova D.R., Zhitkova Yu.V., Vaskaeva G.R. Post-covid syndrome: a review of pathophysiology, neuropsychiatric manifestations and treatment perspectives. Neurology, Neuropsychiatry, Psychosomatics. 2021; 13 (3): 93–8 (in Russ.)]. doi: 10.14412/2074-2711-2021-3-93-98
- Васильев А.С., Шмырев В.И. Биомеханические аспекты патогенеза постковидного синдрома у взрослых. Кремлевская медицина. Клинический вестник. 2022; 1: 100–4 [Vasiliev A.S., Shmyrev V.I. Biomechanical aspects of posT-COVID-19 syndrome pathogenesis in adults. Kremlin Medicine Journal. 2022; 1: 100–4 (in Russ.)]. doi: 10.26269/wv8x-0364
- Коберская Н.Н., Рощин Ф.А. Болезнь Альцгеймера и COVID-19. Неврология, нейропсихиатрия, психосоматика. 2022; 14 (6): 89–97 [Koberskaya N.N., Roshchin F.A. Alzheimer's disease and COVID-19. Neurology, Neuropsychiatry, Psychosomatics. 2022; 14 (6): 89–97 (in Russ.)]. doi: 10.14412/2074-2711-2022-6-89-97
- Дедов Д.В. Новая коронавирусная инфекция: клинико-патогенетические аспекты, профилактика, значение витаминов и микроэлементов. Врач. 2022; 33 (2): 47–9 [Dedov D. New coronavirus infection: clinical and pathogenetic aspects, prophylaxis, importance of vitamins and microelements. Vrach. 2022; 33 (2): 47–9 (in Russ.)]. doi: 10.29296/25877305-2022-02-07
- Николенко В.Н., Ризаева Н.А., Булыгин К.В. и др.Роль оксидативного стресса в развитии болезни Альцгеймера. Неврология, нейропсихиатрия, психосоматика. 2022; 14 (4): 68–74 [Nikolenko V.N., Rizaeva N.A., Bulygin K.V. et al. The role of oxidative stress in the development of Alzheimer's disease. Neurology, Neuropsychiatry, Psychosomatics. 2022; 14 (4): 68–74 (in Russ.)]. doi: 10.14412/2074-2711-2022-4-68-74
- Zubair A.S., McAlpine L.S., Gardin T. et al. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol. 2020; 77 (8): 18–27. doi: 10.1001/jamaneurol.2020.2065
- Huang P., Zhang L.Y., Tan Y.Y. et al. Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms. Transl Neurodegener. 2023; 12 (1): 5. doi: 10.1186/s40035-023-00337-1
- Боголепова А.Н. COVID-19 и болезнь Альцгеймера. Нервные болезни. 2021; 2: 8–12 [Bogolepova AN. COVID-19 and Alzheimer's disease. Nervous diseases. 2021; 2: 8–12 (in Russ.)]. doi: 10.24412/2226-0757-2021-12320
- Путилина М.В., Гришин Д.В. SARS-CoV-2 (COVID-19) как предиктор нейровоспаления и нейродегенерации: потенциальные стратегии терапии. Журнал неврологии и психиатрии им С.С. Корсакова. Спецвыпуски. 2020; 120 (8–2): 58–64 [Putilina M.V., Grishin D.V. SARS-CoV-2 (COVID-19) as a predictor of neuroinflammation and neurodegeneration: potential therapy strategies. S.S. Korsakov Journal of Neurology and Psychiatry. 2020; 120 (8-2): 58–64 (in Russ.)]. doi: 10.17116/jnevro202012008258
- Mavrikaki M., Lee J.D., Solomon I.H. et al. Severe COVID-19 is associated with molecular signatures of aging in the human brain. Nat Aging. 2022; 2 (12): 1130–7. doi: 10.1038/s43587-022-00321-w
- Янишевский С.Н. COVID-19, цереброваскулярная патология и нейродегенерация. Основные закономерности и возможности терапии. Нервные болезни. 2022; 3: 16–23 [Yanishevsky S.N. COVID-19, cerebrovascular pathology and neurodegeneration. Basic patterns and possibilities of therapy. Nervous diseases. 2022; 3: 16–23 (in Russ.)]. doi: 10.24412/2226-0757-2022-12906
- Verkhratsky A., Li Q., Melino S. et al. Can COVID-19 pandemic boost the epidemic of neurodegenerative diseases? Biol Direct. 2020; 15 (1): 28. doi: 10.1186/s13062-020-00282-3
- Dewisme J., Lebouvier T., Vannod-Michel Q. et al. COVID-19 could worsen cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2023; 82 (9): 814–7. doi: 10.1093/jnen/nlad049
- Li C., Liu J., Lin J. et al. COVID-19 and risk of neurodegenerative disorders: A Mendelian randomization study. Transl Psychiatry. 2022; 12 (1): 283. doi: 10.1038/s41398-022-02052-3
- Alonso-Lana S., Marquié M., Ruiz A. et al. Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia. Front Aging Neurosci. 2020; 12: 588872. doi: 10.3389/fnagi.2020.588872
- Saucier J., Comeau D., Robichaud G.A. et al. Reactive gliosis and neuroinflammation: prime suspects in the pathophysiology of post-acute neuroCOVID-19 syndrome. Front Neurol. 2023; 14: 1221266. doi: 10.3389/fneur.2023.1221266
- Zhou Y., Xu J., Hou Y. et al. Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. bioRxiv. 2021; 2021.03.15.435423. doi: 10.1101/2021.03.15.435423
- Wang C., Zhang M., Garcia G. et al. ApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response. Cell Stem Cell. 2021; 28 (2): 331–342.e5. doi: 10.1016/j.stem.2020.12.018
补充文件
